Author

Heike Hofmann-Winkler

German Primate Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 5 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:differential expression· 2 Organism:mouse· 2 Assay:proteomics· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1

Frequent Co-Authors

Stefan PöhlmanniD· 6 shared Markus HoffmanniD· 5 shared Amy Madeleine Kempf· 4 shared Nadine KrügeriD· 4 shared Hans‐Martin JäckiD· 3 shared Luise Graichen· 3 shared Martin Sebastian WinkleriD· 3 shared Prerna AroraiD· 3 shared

Activity by Year

2021-2025 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersMolecular Biology

Stefan PöhlmannORCID

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

MicrobiologybioRxivPreprintJun 26, 2025

Proteolytic processing of the Marburg virus glycoprotein depends on Sec616β and is required for cell entry

Katharina E. Decker, Anke Werner, Markus Hoffmann…·Michael Winkler

This paper identifies Sec61β as essential for proteolytic processing and cell entry of Marburg virus glycoprotein, unlike Ebola virus, and suggests Sec61 as a therapeutic target.

DOI 10.1101/2025.06.26.660697

humanproteomics

𝕏 PostBluesky

Molecular BiologybioRxivPreprintJun 27, 2022

The RNA demethylase FTO controls m6A marking on SARS-CoV-2 and classifies COVID-19 severity in patients

Lionel Malbec, Margot Celerier, Martin Bizet…·François Fuks

This study shows that FTO affects m6A marking on SARS-CoV-2 RNA and correlates with COVID-19 severity in patients.

4 citations

humanmouse

𝕏 PostBluesky

Molecular BiologyCell ReportsPeer-reviewedJun 29, 2021

SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination

Markus Hoffmann, Heike Hofmann-Winkler, Nadine Krüger…·Stefan Pöhlmann

258 citationstop 1%

experimental assay

𝕏 PostBluesky

Molecular BiologyCell ReportsPeer-reviewedApr 1, 2021

SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization

Markus Hoffmann, Lu Zhang, Nadine Krüger…·Stefan Pöhlmann

The paper shows that SARS-CoV-2 mutations from mink reduce antibody neutralization, suggesting potential risks for human infections.

90 citationstop 3%

mousehuman

𝕏 PostBluesky

Molecular BiologyCellPeer-reviewedMar 20, 2021

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination

Markus Hoffmann, Prerna Arora, Rüdiger M. Groß…·Stefan Pöhlmann

940 citationstop 1%

humanexperimental assay

𝕏 PostBluesky

Molecular BiologyEBioMedicinePeer-reviewedMar 1, 2021

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

Markus Hoffmann, Heike Hofmann-Winkler, Joan C. Smith…·Stefan Pöhlmann

This study shows camostat mesylate inhibits SARS-CoV-2 by blocking TMPRSS2 and its metabolite GBPA also has antiviral activity, suggesting no resistance through TMPRSS2-related proteases.

387 citationstop 1%

humanexperimental assay

𝕏 PostBluesky